Access count of this item: 804

Files in This Item:
File Description SizeFormat 
59_301.pdf1.2 MBAdobe PDFView/Open
Title: パクリタキセル・カルボプラチン抵抗性前立腺癌に対してドセタキセル・プレドニンが著効した1例
Other Titles: Successful Treatment with Docetaxel and Prednisolone for Paxlitaxel and Carboplatin-Resistant Prostate Cancer
Authors: 楠川, 直也  KAKEN_name
石田, 泰一  KAKEN_name
棚瀬, 和弥  KAKEN_name
伊藤, 秀明  KAKEN_name
青木, 芳隆  KAKEN_name
大山, 伸幸  KAKEN_name
秋野, 裕信  KAKEN_name
横山, 修  KAKEN_name
Author's alias: Kusukawa, Naoya
Ishida, Hirokazu
Tanase, Kazuya
Ito, Hideaki
Aoki, Yoshitaka
Ooyama, Nobuyuki
Akino, Hironobu
Yokoyama, Osamu
Keywords: Castration-resistant prostate cancer
Issue Date: May-2013
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 59
Issue: 5
Start page: 301
End page: 304
Abstract: A 60-year-old man was examined at a local clinic for difficulty in urinating, and was diagnosed with prostatic hypertrophy. He was referred to our department because his prostate-specific antigen (PSA) level was elevated (276 ng/ml). His Gleason score was 4+3, there was one bone metastasis in the left ileac bone, and multiple lung metastases were present. The patient was accordingly diagnosed with stage D2 prostate cancer. Lutenizing hormone-releasing hormone (LH-RH) analogue treatment was initiated in April 1999, and 9 months later the PSA level had decreased to 4.3 ng/ml. Six years and 9 months after the start of hormone therapy, the cancer had developed into castration-resistant prostate cancer and the PSA level had risen to 43.8 ng/ml. Paclitaxel-carboplatin therapy was therefore initiated. Eight months after the start of chemotherapy, the PSA level had decreased to 25.9 ng/ml, but 6 years and 1 month later it had risen to 925 ng/ml, and the chemotherapy was discontinued. Docetaxel-predonine therapy was initiated in March 2012. Three months after the start of chemotherapy, the PSA level had decreased to 3.1 ng/ml, and the bone metastasis was reduced.
Rights: 許諾条件により本文は2014-06-01に公開
PubMed ID: 23719139
Appears in Collections:Vol.59 No.5

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.